Match Document Document Title
US20130274246 Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes  
The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of...
US20110251243 Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime  
A method of determining a personalised therapeutic regime, comprising: receiving genetic information relating to a patient; determining genetic criteria relevant to a personalised therapeutic...
US20130059004 ORAL DRUG DELIVERY SYSTEM  
An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active...
US20130225540 SUPPRESSION OF GLIAL FIBRILLARY ACIDIC PROTEIN  
Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell....
US20110059170 METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS  
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the...
US20110135695 ORAL DOSAGE FORM FOR CONTROLLED DRUG RELEASE  
An oral dosage form comprising, (i) an erodable core, which core comprises a pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof; and(ii) an erodable coating...
US20150154345 REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER  
Methods of “reprogramming” epigenetic mark readers or erasers to recognize epigenetic marks other than their cognate (or natural) marks are provided. Reprogramming the reader or eraser can offset...
US20110306675 COMPOSITIONS AND METHODS FOR INHIBITING NF-KB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS  
Disclosed are compositions and methods for inhibiting NF-κB mediated cellular proliferation and metastasis. This abstract is intended to be used as a scanning tool for purposes of searching in the...
US20110009351 SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS  
The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF)...
US20140170216 BUPROPION HYDROBROMIDE POLYMORPHS  
Polymorphous and amorphous forms of bupropion hydrobromide are described.
US20130059005 BUPROPION HYDROBROMIDE POLYMORPHS  
Polymorphous and amorphous forms of bupropion hydrobromide are described.
US20100323978 Non-aqueous oil delivery system for ophthalmic drugs  
The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil...
US20080306161 Use of Axomadol for Treatment of Arthrosis Pain  
The use of axomadol for the treatment of pain in arthrosis.
US20130231343 COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS  
The invention described herein pertains to the treatment of multiple sclerosis. In particular, the invention described herein pertains to the treatment of multiple sclerosis using compounds that...
US20140065217 MULTILAYER TABLET  
A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active...
US20060173074 Treatment of restless legs syndrome  
A method for the treatment of restless legs syndrome in a patient using a combination of a COMT-inhibitor, a decarboxylase inhibitor and a dopamine precursor.
US20150133407 COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS  
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical...
US20140051685 THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDIABETES  
The present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic...
US20130108697 MODIFIED RELEASE DOSAGE FORM  
There is provided a modified release dosage form comprising a core coated with a polymeric coat, said polymeric coat comprising one or more rate controlling polymers, said dosage form having a...
US20050256204 Topical phenyl-epinephrine Rosacea treatment  
A near-permanent skin treatment includes photothermolysis of reddened facial skin to induce ischemia. Reperfusion of the photothermolysis treated skin is inhibited by following with regular...
US20120070496 ANTIDEPRESSANT DOSAGE FORM  
A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of...
US20120141491 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS  
The subject application provides small compounds that are able to increase/enhance autophagy in various cells. These compounds are useful in augmenting existing treatments of various cancers,...
US20130034604 EXTENDED RELEASE FORMULATIONS OF DESVENLAFAXINE BASE  
An extended release pharmaceutical composition comprising micronized desvenlafaxine base, at least one pH modifier and at least one release controlling agent and its process for preparation. An...
US20130202705 ALCOHOL-RESISTANT FORMULATIONS  
This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose...
US20150030675 Controlled Release Dosage Forms  
The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55°...
US20100300438 METHOD AND SEDATION DELIVERY SYSTEM INCLUDING A PUMP ASSEMBLY AND A CO-FORMULATION OF FIRST AND SECOND DRUGS  
A drug delivery system includes drug containers, a pump assembly, a sensor, and a controller. The drug containers each contain a different predetermined drug co-formulation of predetermined first...
US20090099202 External Preparation for Athlete's Foot Treatment  
External preparations for athlete's foot treatment capable of enhancing patient's compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at...
US20060165814 Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia  
Combinations comprising vanadium (IV)/(V) compounds and pharmaceutically acceptable amines are provided. Combinations thereof are provided for the treatment or prevention of dyslipidemia,...
US20110070300 EXTENDED RELEASE DOSAGE FORMS OF METOPROLOL  
The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable...
US20060235048 Treatment of connective tissue diseases of the skin  
The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus...
US20050176823 Intra-operative procedure for post-operative pain control  
The instant invention is directed towards an intra-operative method and kit for essentially eliminating pain associated with and resulting from surgical procedures, comprising the administration...
US20110059905 METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE  
Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.
US20130053326 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds  
Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay...
US20060269484 Medicament formulations  
Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a propellant and at lease one medicinally active compound, said propellant comprising at least one...
US20140113927 TREATMENT UTILIZING HYDROPHOBIC WEAK BASES CHEMOTHERAPEUTIC AGENTS AND ILLUMINATION  
Hydrophobic weak base compounds such as hydrophobic weak base chemotherapeutic agents (which are not an anthracycline) for use in the treatment of medical conditions such as proliferative disease...
US20070173478 Compositions for the enhanced treatment of depression  
For treatment of endogenous depression, there is taken in combination an antidepressant, particularly an SSRI or SNRA, and a precursor or inducer of a neurotransmitter, e.g. L-phenylalanine,...
US20110207761 Diversion- and/or abuse-resistant aompositions and methods for making the same  
A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling...
US20070015763 Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist  
This invention relates to combinations of an atypical antipsychotic, for example ziprasidone, and a dopamine agonist, kits containing such combinations, pharmaceutical compositions comprising such...
US20060217394 Treatment of anhedonia  
A therapeutic method for the enhancement of mood in patients afflicted with iatrogenic anhedonia secondary to chronic increases in the availability and/or efficiency of serotonin, with or without...
US20140121283 METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE  
Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not...
US20120232157 METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE  
Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not...
US20120065247 MODULATING IRES-MEDIATED TRANSLATION  
Provided herein are compounds and methods for use in preventing or treating a viral infection mediated by a virus comprising an IRES-containing RNA molecule or cancer related to an increase or...
US20140329907 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS  
Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of...
US20120022086 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS  
Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of...
US20110301452 Microcapsule for local treatment of a tumor and method for positioning a magnetic gradient field guiding magnetic nanoparticles to a target location as well as apparatus for positioning a magnetic gradient field  
A microcapsule for the local treatment of a tumor is proposed. The microcapsule has a support material forming a casing for the microcapsule, an active agent that damages tumor cells, a marker...
US20060240128 Combined immediate release and extended release analgesic composition  
The present invention pertains to an analgesic composition comprising an analgesic drug in an extended release form in combination with an analgesia-enhancing amount of a nontoxic...
US20070027208 Antiparkinsonian Action of Phenylisopropylamines  
A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the...
US20110159050 AMPHIPHILIC PROTEINS AS MORPHOLOGY MODIFIERS  
Disclosed is a process for modifying the morphology and/or polymorphism of an organic substance, which process comprises treating the solid substance, or a solution or dispersion thereof, with one...
US20140018436 DEUTERIUM-ENRICHED BUPROPION  
The present application describes deuterium-enriched bupropion, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
US20110130463 DEUTERIUM-ENRICHED BUPROPION  
The present application describes deuterium-enriched bupropion, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.